Sorrento Gets FDA Approval For Phase 1 Study For COVID Treatment; Shares Up 5%

索伦托获得FDA批准用于COVID治疗的1期研究;股价上涨5%

2021-03-03 07:38:39 RTTNews

本文共496个字,阅读需2分钟

Shares of Sorrento Therapeutics Inc. gained over 5% in extended trading session on Tuesday after the company FDA cleared its Investigational New Drug application for early stage study of STI-2099 in both healthy volunteers and COVID-19 patients. Sorrento Therapeutics said it received clearance from the FDA for its Investigational New Drug application for its Phase 1 study of the safety and pharmacokinetics of intranasal STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19. Sorrento is currently evaluating an intravenous formulation of this potent antibody, STI-2020 (IV), in a Phase 1 study in healthy volunteers and COVID-19 patients with mild symptoms. "We plan to use our intranasal formulation technology, which allows administering a drug via simple drops in the nose, for other antibodies we are currently developing with a goal of providing coverage against all variants of the SARS-CoV-2 virus that might evade inhibition from treatment with existing therapies," said Dr. Henry Ji, Chairman and CEO of Sorrento. SRNE closed Tuesday's trading at $9.44, down $0.81 or 7.90%, on the Nasdaq. The stock, however, gained $0.56 or 5.93% in the after-hours trade. For comments and feedback contact: editorial@rttnews.com Business News
索伦托治疗公司(Sorrento Therapeutics Inc.)的股价在周二延长交易时段上涨逾5%,此前该公司FDA批准了其用于在健康志愿者和COVID-19患者中进行STI-2099早期研究的新药申请。 Sorrento Therapeutics表示,该公司已获得FDA的新药研究申请许可,用于其鼻内注射STI-2099(COVIDROPS)在健康志愿者和轻度COVID-19患者中的安全性和药代动力学1期研究。 索伦托目前正在对这种强效抗体的一种静脉注射制剂STI-2020(IV)进行评估,在健康志愿者和症状轻微的新冠肺炎患者中进行1期研究。 Sorrento公司董事长兼首席执行官Henry Ji博士说:“我们计划使用我们的鼻内制剂技术,该技术允许通过简单滴鼻的方式给药,用于我们目前正在开发的其他抗体,目的是为所有可能逃避现有疗法抑制的新型冠状病毒病毒变种提供覆盖范围。” SRNE周二收盘报9.44美元,下跌0.81美元,跌幅7.90%。不过,该股在盘后交易中上涨0.56美元或5.93%。 如需评论和反馈,请联系:editorial@rttnews.com 商业新闻

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文